NIH supports milestone-driven Down syndrome clinical trial development with up to two years of planning and a possible three-year clinical trial phase, for a maximum of five years.
Funder: National Institutes of Health
Due Dates: October 15, 2026 (Application) | June 15, 2027 (Application) | June 15, 2028 (Application)
Funding Amounts: $3,000,000 estimated program funding; project budgets based on actual needs; up to five years
Summary: Supports milestone-driven, phased clinical trials addressing critical and co-occurring health conditions in individuals with Down syndrome.
Key Information: Clinical trials are required; transition from R61 to R33 depends on milestone completion and NIH approval.
The NIH INCLUDE Project supports research to improve health and quality of life for individuals with Down syndrome. This R61/R33 opportunity funds clinical trial development and implementation for critical and co-occurring conditions, emphasizing knowledge that translates into new, enhanced, or tailored therapies. Projects may address a particular developmental stage or the lifespan, including outcomes and health services research.
Supported work includes adapting existing drugs and interventions, developing technologies, improving screening and healthcare delivery, and addressing barriers to care. Solutions should be implementable and sustainable beyond the research setting, with potential to address healthcare disparities. The phased approach supports preliminary data collection, collaboration development, and trial preparation before clinical trial implementation. Basic-science-focused projects and projects not needing a phased approach are directed toward other funding mechanisms.